Literature DB >> 23437769

Exploring novel KDR inhibitors based on pharmaco-informatics methodology.

R K Kar1, P Suryadevara, B R Sahoo, G C Sahoo, M R Dikhit, P Das.   

Abstract

Kinase-insert domain-containing receptor (KDR) is one of the important mediators of Vascular endothelial growth factor (VEGF) function in endothelial cells. Inhibition of KDR can be therapeutically advantageous for treatment of a number of diseases. The present study focuses on exploring novel KDR inhibitors by means of pharmaco-informatics methodologies. Three-dimensional quantitative structure-activity relationship (3D-QSAR) analysis by atom-based pharmacophore mapping over a set of 85 molecules provides a proposition regarding the molecular fingerprint that can be optimized for designing more active inhibitors. The model was statistically validated with Q(2) = 0.865 for training and r(2) = 0.789, Pearson-r = 0.903 for test set molecules; r(2)(0.925) by external validation suggests model robustness and indicates it as a strong query for screening any compound library. Virtual screening shows the importance of active site and hinge region residue for interaction with KDR inhibitors. Remarkably the retrieved hits contain a urea backbone, implicating urea derivatives as promising candidate for designing KDR inhibitors. The hydrophobicity of active site, which has until now been overlooked, has been raised into the picture by this study. This can impact on KDR drug development. The study thus quantifies crucial structural requirements necessary for a favourable interaction with the receptor binding site while the cooperative pattern provides important structural clues to chemists for framing potent medicinal agents in future.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23437769     DOI: 10.1080/1062936X.2013.765912

Source DB:  PubMed          Journal:  SAR QSAR Environ Res        ISSN: 1026-776X            Impact factor:   3.000


  6 in total

1.  Vascular endothelial growth factor receptor-2 (VEGFR-2) inhibitors: development and validation of predictive 3-D QSAR models through extensive ligand- and structure-based approaches.

Authors:  Rino Ragno; Flavio Ballante; Adele Pirolli; Richard B Wickersham; Alexandros Patsilinakos; Stéphanie Hesse; Enrico Perspicace; Gilbert Kirsch
Journal:  J Comput Aided Mol Des       Date:  2015-07-21       Impact factor: 3.686

2.  Deciphering the role of the AT-rich interaction domain and the HMG-box domain of ARID-HMG proteins of Arabidopsis thaliana.

Authors:  Adrita Roy; Arkajyoti Dutta; Dipan Roy; Payel Ganguly; Ritesh Ghosh; Rajiv K Kar; Anirban Bhunia; Jayanta Mukhopadhyay; Shubho Chaudhuri
Journal:  Plant Mol Biol       Date:  2016-08-09       Impact factor: 4.076

3.  Expedient synthesis of the pentasaccharide repeating unit of the O-antigen of Escherichia coli O86 and its conformational analysis.

Authors:  Ishani Bhaumik; Rajiv Kumar Kar; Anirban Bhunia; Anup Kumar Misra
Journal:  Glycoconj J       Date:  2016-06-04       Impact factor: 2.916

4.  Phosphorylation of Translation Initiation Factor 2-Alpha in Leishmania donovani under Stress Is Necessary for Parasite Survival.

Authors:  Kumar Abhishek; Abul Hasan Sardar; Sushmita Das; Ashish Kumar; Ayan Kumar Ghosh; Ruby Singh; Savita Saini; Abhishek Mandal; Sudha Verma; Ajay Kumar; Bidyut Purkait; Manas Ranjan Dikhit; Pradeep Das
Journal:  Mol Cell Biol       Date:  2016-12-19       Impact factor: 5.069

5.  Biophysical Characterization of Essential Phosphorylation at the Flexible C-Terminal Region of C-Raf with 14-3-3ζ Protein.

Authors:  Anirban Ghosh; Bhisma Narayan Ratha; Nilanjan Gayen; Kamal H Mroue; Rajiv K Kar; Atin K Mandal; Anirban Bhunia
Journal:  PLoS One       Date:  2015-08-21       Impact factor: 3.240

6.  Computational elucidation of structural basis for ligand binding with Leishmania donovani adenosine kinase.

Authors:  Rajiv K Kar; Md Yousuf Ansari; Priyanka Suryadevara; Bikash R Sahoo; Ganesh C Sahoo; Manas R Dikhit; Pradeep Das
Journal:  Biomed Res Int       Date:  2013-07-24       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.